Trial Profile
A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ficlatuzumab (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AVEO Oncology
- 01 Jul 2018 Results (n=15) of phase 1 published in the Clinical Pharmacology in Drug Development.
- 07 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 29 Sep 2014 Results of a retrospective exploratory analysis in VeriStrat-selected patients with NSCLC were presented at the 2014 Congress of the European Society for Medical Oncology (ESMO), according to an AVEO Oncology media release.